pharmaceuticals

Major Biopharma Catalysts on the December FDA Calendar

Posted: November 29, 2019 at 10:40 am

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Posted: November 27, 2019 at 9:00 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Posted: November 25, 2019 at 10:02 am

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G. (NYSE: NVS) will be acquiring the firm. The transaction was unanimously approved by the ...
Read Full Story »

Will Medicines Co Be the Next Target of Novartis?

Posted: November 19, 2019 at 10:40 am

Medicines Co. (NASDAQ: MDCO) shares shot up on Tuesday after it was reported that Novartis A.G. (NYSE: NVS) might be eyeing this company as its newest acquisition. Currently, Medicines has ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Posted: November 12, 2019 at 8:50 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Posted: October 29, 2019 at 10:20 am
Last updated: November 11, 2019 10:28 am

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) reported their most recent quarterly results before the opening bell Tuesday. Despite some trepidation for the health care sector, ...
Read Full Story »

Merck and Pfizer Earnings: What to Expect

Posted: October 28, 2019 at 1:25 pm

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Is Walgreens Getting Enough Out of Q4 Earnings?

Posted: October 28, 2019 at 9:50 am

Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The retailer said that it had $1.43 in earnings per share (EPS) ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Posted: October 25, 2019 at 9:59 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Eli Lilly Just Couldn’t Get It Together in Q3

Posted: October 23, 2019 at 10:25 am

When Eli Lilly and Co. (NYSE: LLY) released its third-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had $1.48 in earnings per share ...
Read Full Story »

How Biotech and Big Pharma Have Upside Heading Into Earnings

Posted: October 19, 2019 at 6:45 am

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Are Shareholders Getting Enough in the Achillion Acquisition?

Posted: October 16, 2019 at 9:45 am

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). While shares are up sharply ...
Read Full Story »

Why This Neuromuscular Disorder Study Could Be the Next Big Thing

Posted: October 15, 2019 at 12:35 pm

Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial. Specifically, the results are from Reata’s MOXIe Phase ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday

Posted: October 14, 2019 at 12:10 pm

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.00 in earnings per ...
Read Full Story »

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Posted: October 14, 2019 at 10:05 am

Allergan PLC (NYSE: AGN) finally has announced that its shareholders have voted to approve the company’s acquisition by AbbVie Inc. (NYSE: ABBV). The acquisition is expected to close in early ...
Read Full Story »